Brief: Inhibikase Therapeutics To Provide Trial Update For Risvodetinib On March 9
07/03/2024 15:26
March 7 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS TO PROVIDE TRIAL UPDATE FOR
RISVODETINIB
AT THE 2024 INTERNATIONAL CONFERENCE ON ALZHEIMER’S AND
PARKINSON’S DISEASES AND RELATED NEUROLOGICAL DISORDERS
Source text for Eikon: ID:nGNX1mh3N8
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary